EU Lawmakers Move to Reshore Vital Drug Production

80% of API Imports Leave Europe Exposed to Supply Shocks

The core of the vulnerability lies in Active Pharmaceutical Ingredients, the chemical compounds that actually give a medicine its therapeutic effect.

According to industry data analysed on Tuesday, 28 July, the European Union imports approximately 80% of its APIs from non-EU countries, primarily China and India.

This heavy reliance was highlighted in a recent briefing titled "EU API Dependency: Critical Medicines Act & Reshoring", which details the extent of the continent's exposure to global trade friction.

Experts warn that this concentration of production in a few geographic regions creates a single point of failure that could paralyse European healthcare systems.

If a geopolitical conflict, trade dispute, or natural disaster were to disrupt shipping lanes or export policies, European pharmacies could run dry of essential medications within weeks.

The situation is particularly acute for generic drugs, which make up the vast majority of prescriptions filled across the continent but operate on razor-thin margins that discourage domestic manufacturing.

• The EU imports 80% of its Active Pharmaceutical Ingredients from abroad.
• Dependency is concentrated in China and India.
• Generic drugs are most at risk due to low profit margins.

The briefing from debuglies.com notes that the cost of producing APIs in Europe has historically been prohibitive due to stricter environmental regulations and higher energy costs compared to Asia.

Consequently, pharmaceutical companies gradually shifted production overseas, a process that hollowed out the continent's industrial base for drug synthesis.

Now, officials admit that this economic efficiency came at the cost of strategic security.

The Critical Medicines Act seeks to address this imbalance by creating financial incentives for companies to reshore production lines.

This includes subsidies for building new factories, tax breaks for research and development, and potentially stricter procurement rules that favour EU-made ingredients for public health contracts.

The goal is not to close borders to trade, but to ensure that Europe has the capacity to produce its own critical medicines in times of emergency.

"We cannot allow the health of our citizens to be held hostage by supply chains halfway around the world," a policy analyst noted in the briefing.

The debate now centres on how quickly this transition can occur without causing price spikes for consumers who are already facing a cost-of-living crisis.

Critical Medicines Act Forces Reshoring of Key Pharmaceutical Plants

Legislators are moving fast to turn the rhetoric of autonomy into concrete law through the Critical Medicines Act.

According to a detailed analysis published on Tuesday, 26 May, the legislation is poised to have a transformative impact on pharmaceutical manufacturing across the bloc.

The report from PharmTech.com outlines how the Act will function as a catalyst for reshoring, effectively reversing the de-industrialisation trends of the last forty years.

The Act introduces a mechanism for "Strategic Stockpiling" and "Critical Manufacturing Lists", identifying which medicines are essential for national security and therefore must be produced, at least in part, within European borders.

This represents a major intervention in the free market, driven by the recognition that the market alone failed to protect patients during recent shortages.

• The Critical Medicines Act was analysed in depth on 26 May 2026.
• It identifies lists of medicines that must be produced domestically.
• The law aims to reverse four decades of de-industrialisation.

One of the key provisions discussed in the analysis is the simplification of regulatory pathways for plants that manufacture critical APIs.

Currently, the bureaucratic burden of opening a new chemical plant in the EU is immense, often deterring investment.

The Act proposes to streamline these processes, treating pharmaceutical infrastructure similarly to defence infrastructure.

Furthermore, the legislation is expected to include clauses on "forced technology transfer" prevention, ensuring that European research and innovation remains within the continent rather than being licensed out to foreign manufacturers who then control the supply.

Industry leaders have welcomed the move, arguing that a level playing field is needed to compete with state-subsidised entities in other parts of the world.

However, some caution that reshoring will take time; building a pharmaceutical plant and getting it licensed can take up to five years.

Therefore, the Act also includes measures for supply chain diversification in the interim, seeking to broaden the list of supplier countries to reduce reliance on any single nation.

The PharmTech.com analysis emphasises that supply resilience is the ultimate objective, even if the path to achieving it requires a mix of domestic production and diversified foreign partnerships.

Pharmacists Struggle to Fill Prescriptions as Shortages Persist

While policymakers debate the finer points of industrial strategy, the reality of drug shortages is already being felt on high streets across Europe.

Renew Europe, a prominent political group in the European Parliament, has been vocal about the urgent need for the Critical Medicines Act, citing the distress caused to patients and healthcare providers.

In a statement released on Tuesday, 12 May, the group declared that the Act would put an end to critical medicine shortages "once and for all".

For months, pharmacists in Germany, France, and Italy have reported difficulties in securing stocks of basic antibiotics, insulin, and cancer treatments.

These shortages force doctors to switch patients to alternative medications that may be less effective or have worse side effects, increasing the burden on an already strained healthcare system.

• Renew Europe issued a statement on 12 May 2026.
• Pharmacists report shortages of antibiotics and insulin.
• Doctors are forced to prescribe less effective alternatives.

The human cost of these supply chain failures is significant.

Vulnerable groups, such as the elderly and those with chronic conditions, are disproportionately affected when their regular medication becomes unavailable.

A representative from Renew Europe argued that the situation is untenable in a wealthy region like Europe, stating that citizens should not have to worry about whether their pharmacy will have the pills they need to survive.

The Critical Medicines Act aims to solve this by mandating that manufacturers guarantee supply continuity for the European market as a condition of operating within the bloc.

This could involve legal obligations to hold minimum stocks of critical medicines at all times, preventing companies from exporting products to higher-paying markets when European stocks run low.

Additionally, the legislation proposes better data transparency, requiring companies to report potential shortages earlier so that authorities can intervene before shelves go empty.

This data-driven approach is designed to move the system from reactive crisis management to proactive prevention.

For patients, these changes cannot come soon enough.

The anxiety of not knowing if a life-saving prescription can be filled is a modern phenomenon that European leaders are now desperate to eradicate.

Billions in Investment Required to Rebuild Domestic Factory Lines

Achieving the vision of a self-sufficient Europe will come with a hefty price tag, requiring billions of euros in investment to rebuild the continent's pharmaceutical manufacturing base.

Experts point out that you cannot simply turn a switch and restart factories that were closed twenty years ago; the skilled labour has moved on, and the machinery has been scrapped.

Rebuilding this capacity requires a long-term financial commitment from both the public and private sectors.

The IIEA report highlights that this investment should be viewed not as a cost, but as an insurance premium for the continent's future stability.

However, convincing finance ministries to release substantial funds during a period of fiscal tightening is a difficult political sell.

To bridge the gap, the EU is looking at a combination of grants from the Horizon Europe research programme and loans from the European Investment Bank.

• Rebuilding capacity will cost billions of euros.
• Skilled labour and machinery must be rebuilt from scratch.
• Funding may come from EU grants and European Investment Bank loans.

There is also the issue of energy prices.

Pharmaceutical manufacturing is energy-intensive, requiring vast amounts of electricity and heat for chemical synthesis and sterilisation.

European energy prices have historically been higher than those in the US or Asia, putting the continent at a competitive disadvantage.

To make reshoring viable, the Critical Medicines Act may need to be accompanied by broader industrial policies that reduce the cost of energy for heavy industry.

Some analysts have suggested creating "green hydrogen" hubs specifically for pharmaceutical manufacturing to lower the carbon footprint and the energy cost simultaneously.

Furthermore, there is a push to rethink environmental regulations.

While Europe is committed to high environmental standards, there are calls to streamline the approval process for chemical plants without lowering the actual standards.

This would reduce the administrative drag that currently slows down construction.

Industry sources confirmed that they are ready to invest, provided the regulatory environment is predictable and the financial incentives are sufficient to cover the higher operating costs in Europe.

The negotiation over these subsidies and regulations is currently underway in Brussels, with the final text of the Act expected to be hammered out in the coming months.

Brussels Bets on Local Production to Shield Against Future Crises

As the legislation moves through the corridors of power in Brussels, the broader implication is clear: Europe is abandoning the naive belief that global trade will always remain open and peaceful.